News
Menstrual cups could reduce vaginal infections, trial shows
Researchers have found menstrual cups may provide beneficial results to women’s reproductive health
The use of menstrual cups may result in fewer infections and improved vaginal health, a new trial has found.
Researchers from Liverpool School of Tropical Medicine, in collaboration with researchers from Kenya and the US, investigated options for girls and young women in low-and-middle-income countries to manage menstruation with comfort and dignity and to improve health outcomes.
As part of the Cups or Cash for Girls (CCG) trial, they assessed the impact of the menstrual cup on girls’ incidence of herpes simplex virus type 2 (HSV-2).
Two new papers from the CCG trial provided evidence that the menstrual cup may provide beneficial results to menstruators’ reproductive health and could be an acceptable and long-lasting solution to manage menstruation.
One study, published in eClinicalMedicine, showed that girls provided with cups had a 33 per cent reduction in HSV-2 compared to the control group. HSV-2, the virus that causes genital herpes, can triple an individual’s risk of becoming infected with HIV.
The study involved 4,137 Kenyan schoolgirls between 16-18 across 96 secondary school in western Kenya.
Schools were allocated to four treatment groups: menstrual cup, conditional cash transfer, combination of cup and cash transfer, and usual menstrual practice (control). Girls were followed for three years or until they completed secondary school.
Dr Garazi Zulaika, post-doctoral research associate at LSTM and lead author on the paper said: “We were interested to know whether a long-lasting, sustainable, and hygienic menstrual solution would be used by girls and be effective in improving their schooling and sexual and reproductive health.
“Our results show that menstrual cups were well-accepted by girls’ as well as protective against infections, highlighting how they can be a great option for menstrual hygiene management while also having significant health impacts.”
A sub-study, published in PLoS Medicine, followed 436 girls and assessed whether menstrual cups reduced rates of bacterial vaginosis or changed the vaginal microbiome.
It found that girls given menstrual cups had a 24 per cent reduction in bacterial vaginosis compared with controls. Additionally, there was a 37 per cent relative increase in Lactobacillus crispatus, indicating cups could improve or maintain a healthy vaginal microbiome.
Elizabeth Nyothach, trial manager at the Kenya Medical Research Institute, who partnered with LSTM on the study, said: “Menstrual cups can be used for up to ten years, offer long term health benefits, reduce waste, and provide financial savings as there is no longer a need for menstruators to buy single use pads and tampons every month.”
Insight
Topical HRT protects bone density in women with period loss – study
Transdermal HRT best protects bone density in women with functional hypothalamic amenorrhoea, a condition that stops periods, a review of trials has found.
The meta-analysis pooled randomised clinical trials involving 692 participants and found transdermal hormone replacement therapy and teriparatide increased bone mineral density by between 2 and 13 per cent.
Functional hypothalamic amenorrhoea can follow anorexia or intense exercise. Bone mineral density measures bone strength and the amount of mineral in bone.
Around half of women with the condition have low bone mineral density, compared with about 1 per cent of healthy women, and their fracture risk is up to seven times higher.
The research was conducted by scientists at Imperial College London and Imperial College Healthcare NHS Trust.
Professor Alexander Comninos, senior author of the study and consultant endocrinologist at the trust, said: “Bone density is lost very rapidly in FHA and so addressing bone health early is very important to reduce the lifelong risk of fractures.
“Our study provides much needed comparisons of all the available treatments from all available studies.
“Clearly the best treatment is to restore normal menstrual cycles and therefore oestrogen levels through various psychological, nutritional or exercise interventions – but that is not always possible.
“The foundation for bone health is good calcium and vitamin D intake (through diet and/or supplements) but we have additional treatments that are more effective.”
When FHA is diagnosed, clinicians first try to restore periods through lifestyle measures, including psychological and dietary support, but these can fail. Guidelines then recommend giving oestrogen, though the best form was unclear.
The team reviewed all prior randomised trials comparing therapies, including oral and transdermal oestrogen, and also assessed teriparatide, a prescription bone-building drug used for severe osteoporosis.
They found no significant benefit for oral contraceptive pills or oral hormone therapy.
A recent UK audit reported that about a quarter of women with anorexia-related FHA are prescribed the oral contraceptive pill for bone loss; the study suggests using transdermal therapy instead.
Comninos said: “Our goal is simple: to help women receive the right treatment sooner and to protect their bone health in the long-term.
“We hope this study provides clinicians with better evidence to choose transdermal oestrogen when prescribing oestrogen and so inform future practice guidelines.
“Right now, millions of women with FHA may not be receiving the best treatments for their bone health.”
Insight
AI cuts interval breast cancers in Swedish trial
Mental health
Fear of ageing may age women faster, study suggests
-
Features4 weeks agoWomen’s health enters a new era – the trends shaping femtech in 2026
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Features4 weeks agoBest menopause apps and products for 2026
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoHigher maternal blood pressure increases risk of pregnancy complications, study finds
-
Hormonal health4 weeks agoXella Health closes US$3.7 million in pre-seed financing
-
Insight4 weeks agoInside the first wave of speakers confirmed for Women’s Health Week USA 2026






